AbbVie’s Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial

Bitget2026/10/22 13:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AbbVie’s investigational lutikizumab met the primary goal in the Phase 3 INTREPID trial for adults and adolescents with moderate to severe hidradenitis suppurativa.
Treatment improved clinical response versus placebo, reduced skin pain and disease flares, with no new safety concerns identified.
Results will be presented at a future medical congress.
Additional trial data are expected in 2027 to support regulatory submissions in the second half of that year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610220900PR_NEWS_USPR_____CG74397) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AbbVie’s Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial

You may also like

Crypto prices